Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

Biosimilars: SOP for Restriction Enzyme Digestion and Mapping – V 2.0

Posted on By


Biosimilars: SOP for Restriction Enzyme Digestion and Mapping – V 2.0


Standard Operating Procedure for Restriction Enzyme Digestion and Mapping in Biosimilar Research

Department Biosimilars
SOP No. SOP/BS/007/2025
Supersedes SOP/BS/007/2022
Page No. Page 1 of 11
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To establish a standard method for performing restriction enzyme digestion and mapping of plasmid DNA for verification of insert orientation, integration, and overall vector integrity during biosimilar development.

2. Scope

This SOP applies to the Biosimilars R&D team engaged in molecular biology operations involving plasmid validation post-cloning and prior to expression studies.

3. Responsibilities

  • Molecular Biologist: Designs digestion strategy, selects appropriate enzymes, and interprets results.
  • Research Assistant: Prepares reaction mixes and performs electrophoresis.
  • QA Personnel: Verifies documentation of mapping results and digestion patterns.
See also  Biosimilars: SOP for ELISA-Based Screening of Clones - V 2.0

4. Accountability

The Head of Molecular Biology is accountable for ensuring all plasmid digestion and mapping procedures are compliant with molecular verification protocols and documented accordingly.

5. Procedure

5.1 Selection of Restriction Enzymes

  1. Choose enzymes based on:
    • Vector backbone map
    • Insert flanking regions
    • Expected fragment sizes
  2. Use double or single digests as needed to differentiate between orientations or configurations.

5.2 Preparation of Digestion Reaction

  1. Prepare the reaction mix in a sterile microcentrifuge tube:
    • Plasmid DNA: 500–1000 ng
    • 10X Buffer: 2 µL
    • Restriction Enzyme(s): 1 µL each
    • Nuclease-Free Water: To make up to 20 µL
  2. Gently mix by tapping and spin down briefly.
  3. Incubate at 37°C for 1–2 hours (as per enzyme manufacturer guidelines).

5.3 Agarose Gel Electrophoresis

  1. Prepare 1% or 1.5% agarose gel with safe DNA stain (e.g., ethidium bromide or SYBR Safe).
  2. Load 5 µL of digested sample mixed with 1 µL of 6X loading dye.
  3. Include 1 kb or 100 bp DNA ladder as reference.
  4. Run gel at 80–100V for 45–60 minutes in 1X TAE buffer.
  5. Visualize bands using UV transilluminator and photograph gel for records.
See also  Biosimilars: SOP for Transient Transfection Methods - V 2.0

5.4 Mapping and Result Interpretation

  1. Compare observed bands with predicted digestion pattern from in-silico map (e.g., SnapGene or NEBcutter).
  2. Record:
    • Fragment sizes
    • Band intensity
    • Lane and ladder references
  3. Document findings in Plasmid Mapping Record (Annexure-1).

5.5 Troubleshooting and Repeat Analysis

  1. If unexpected bands appear:
    • Check for star activity or incomplete digestion.
    • Repeat with fresh enzyme or alternative buffer.
    • Use additional enzymes to confirm map.

5.6 Documentation and Archiving

  1. Label gel image with date, sample ID, and enzyme names.
  2. Attach to printed mapping report and file in project record folder.
  3. Store digital copy in central repository with access control.

6. Abbreviations

  • SOP: Standard Operating Procedure
  • TAE: Tris Acetate EDTA Buffer
  • QA: Quality Assurance
See also  Biosimilars: SOP for Stable Cell Line Development - V 2.0

7. Documents

  1. Plasmid Mapping Record (Annexure-1)
  2. Gel Image Archive Log (Annexure-2)

8. References

  • ICH Q5B – Expression Construct Analysis
  • WHO Guidelines on DNA-Based Biologics
  • CDSCO Recombinant Product Evaluation Manual

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Plasmid Mapping Record

Date Plasmid ID Enzymes Used Expected Bands (bp) Observed Bands (bp) Status
03/05/2025 pCMV-rhEPO EcoRI, HindIII 3000, 1800 3000, 1800 Verified

Annexure-2: Gel Image Archive Log

Date Plasmid ID Image Filename Operator Location
03/05/2025 pCMV-rhEPO gel_rhEPO_03052025.jpg Sunita Reddy Lab Server/Gels/May25

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
04/05/2025 2.0 Clarified mapping interpretation and added Gel Image Log Annual SOP update
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: Tablets: SOP for Visual Inspection of Packed Tablets – V 2.0
Next Post: Creams: SOP for Monitoring and Maintaining Vacuum Levels during Cream Processing – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version